Biopharmaceutical company developing therapies for severe metabolic, oncologic, and psychiatric disorders.
Corcept Therapeutics Incorporated specializes in the discovery, development, and commercialization of pharmaceuticals aimed at addressing severe metabolic, oncologic, and neuropsychiatric disorders within the United States. Central to its product offerings is Korlym (mifepristone) tablets, a once-daily oral medication designed specifically for adult patients suffering from hyperglycemia caused by hypercortisolism associated with endogenous Cushing's syndrome. This treatment is tailored for individuals who have type 2 diabetes mellitus or glucose intolerance and have either failed surgery or are not viable candidates for surgical intervention.
In addition to Korlym, Corcept Therapeutics is actively advancing its pipeline with promising candidates. Notably, relacorilant is under development for the treatment of Cushing's syndrome, offering potential alternatives for patients facing this challenging condition. Moreover, the company is exploring nab-paclitaxel in combination with relacorilant, which has completed Phase II clinical trials aimed at addressing advanced ovarian tumors and cortisol excess.
Further expanding its therapeutic scope, Corcept Therapeutics is engaged in the development of selective cortisol modulators. These innovations are targeted towards treating metastatic castration-resistant prostate cancer and addressing antipsychotic-induced weight gain among other associated disorders. Additionally, the company is actively researching FKBP5 gene expression assays, underscoring its commitment to advancing precision medicine approaches.
Founded in 1998 and headquartered in Menlo Park, California, Corcept Therapeutics Incorporated continues to leverage its expertise in clinical research and drug development to bring forward novel therapies that aim to improve the quality of life for patients grappling with complex medical conditions.